Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Vismodegib by Genentech USA for Refractory Multiple Myeloma: Likelihood of Approval
Vismodegib is under clinical development by Genentech USA and currently in Phase II for Refractory Multiple Myeloma. According to GlobalData,...
Data Insights
Vismodegib by Genentech USA for Meningioma: Likelihood of Approval
Vismodegib is under clinical development by Genentech USA and currently in Phase II for Meningioma. According to GlobalData, Phase II...